Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some claims about labeled dizziness/somnolence and labeled indications (fibromyalgia, neuropathic pain conditions, and partial-onset seizures adjunctive therapy) are supported by the provided label excerpts, but multiple claims about muscle excitability/motor function/torque/force and specific mechanisms or functional outcomes are not supported by the supplied prescribing information and therefore significantly reduce alignment.
Category Scores
Accurate Statements
Lyrica (pregabalin) is used to manage neuropathic pain.
Supported in general by label indications for neuropathic pain conditions (e.g., diabetic peripheral neuropathy and postherpetic neuralgia) under 1 INDICATIONS AND USAGE.
Lyrica (pregabalin) is used to manage fibromyalgia.
Supported by 1 INDICATIONS AND USAGE (Management of fibromyalgia).
Lyrica (pregabalin) is used to manage epilepsy.
Partially supported: label indication is adjunctive therapy for partial-onset seizures (not broadly stated as 'epilepsy') under 1 INDICATIONS AND USAGE.
Lyrica can cause drowsiness and fatigue.
Supported by 5.5 Dizziness and Somnolence stating LYRICA may cause dizziness and somnolence; fatigue specifically not shown, but drowsiness is consistent with 'somnolence' in the excerpt.
Lyrica can cause postural dizziness.
Partially supported: label excerpt states dizziness and somnolence; 'postural' is not specified in the provided text.
Lyrica can cause headaches.
Unsupported Statements
Pregabalin reduces muscle excitability.
No support in the provided label excerpts (mechanism section provided does not describe 'muscle excitability' reduction).
Reduced muscle excitability can lead to decreased muscle strength and endurance.
Not supported by the provided label excerpts.
Pregabalin can impair motor function, including muscle force.
Not supported by the provided label excerpts.
Pregabalin can impair motor function, including muscle fatigue resistance.
Not supported by the provided label excerpts.
Pregabalin treatment reduced muscle torque in healthy individuals.
No study results or claims about muscle torque/healthy individuals appear in the supplied label excerpts.
Pregabalin treatment reduced force production in healthy individuals.
No study results or claims about force production/healthy individuals appear in the supplied label excerpts.
Postural dizziness can increase the risk of falls and other injuries during exercise.
The provided label excerpt discusses dizziness/somnolence impairing tasks like driving/operating machinery, but does not mention postural dizziness, falls, injuries, or exercise-related risk.
Lyrica can cause headaches.
Headache is not included in the provided warnings/adverse-reaction excerpts.
Frequent or severe headaches can distract from physical activity and potentially lead to reduced performance.
Not supported by the provided label excerpts.
Contradictions
Low
AI Statement
Postural dizziness can increase the risk of falls and other injuries during exercise.
Label Reference
5.5 Dizziness and Somnolence excerpt
Important Omissions
For the epilepsy claim, the label specifies 'adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older' rather than a general epilepsy indication.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims about muscle/motor impairment and exercise-related fall/injury risk could mislead risk perception beyond what the provided label supports. Dizziness/somnolence is supported, but additional functional claims are not.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims regarding muscle excitability/motor function outcomes and exercise/falls risk are not supported by the supplied prescribing information excerpts.
Suggested Improvement
Limit statements to label-supported content from the provided sections: (1) list specific labeled indications under 1 INDICATIONS AND USAGE, (2) describe dizziness and somnolence per 5.5 without adding unsupported modifiers (e.g., 'postural' falls/exercise injury risk), and (3) remove or source muscle torque/force/motor impairment claims from the prescribing information if present elsewhere in the full label.